betaine has been researched along with Cerebro-Hepato-Renal Syndrome in 2 studies
glycine betaine : The amino acid betaine derived from glycine.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, R | 1 |
| Chen, L | 1 |
| Jiralerspong, S | 1 |
| Snowden, A | 1 |
| Steinberg, S | 1 |
| Braverman, N | 1 |
| Chegary, M | 1 |
| Te Brinke, H | 1 |
| Doolaard, M | 1 |
| Ijlst, L | 1 |
| Wijburg, FA | 1 |
| Wanders, RJ | 1 |
| Houten, SM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot, Open Label Trial Assessing the Safety and Efficacy of Betaine in Children With Peroxisome Biogenesis Disorders.[NCT01838941] | Phase 3 | 12 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
C26/C22 ratio in plasma is a recognized biomarker for very long chain fatty acid (normal range: 0.002-0.018). It was measured twice before the beginning of treatment and measured once at the end. (NCT01838941)
Timeframe: 6 months
| Intervention | ratio (Mean) | |
|---|---|---|
| Baseline | At 6 months | |
| Betaine | 0.180 | 0.188 |
2 other studies available for betaine and Cerebro-Hepato-Renal Syndrome
| Article | Year |
|---|---|
Recovery of PEX1-Gly843Asp peroxisome dysfunction by small-molecule compounds.
Topics: Adenosine Triphosphatases; Amino Acid Substitution; ATPases Associated with Diverse Cellular Activit | 2010 |
Characterization of L-aminocarnitine, an inhibitor of fatty acid oxidation.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Acetyl-CoA C-Acyltransferase; Acyl-CoA Dehydrogenase, Long-Chain; | 2008 |